紫龙金片联合PC方案治疗原发性非小细胞肺癌临床研究

Clinical Study on Treatment of Primary Non-small Cell Lung Cancer with Zilongjin Tablets Combined with PC Chemotherapy

目的:观察紫龙金片联合PC化疗方案治疗原发性非小细胞肺癌的临床疗效。方法:选取53例原发性非小细胞肺癌患者为研究对象,随机分为对照组和治疗组。对照组24例,单纯给予PC方案进行化疗;治疗组25组,在对照组基础上联合中成药紫龙金片治疗。比较两组患者鳞状上皮细胞癌抗原(squamous cell carcinoma antigen,SCCAg)、CYFRA21-1水平,评价生存质量,观察中医证候积分及不良反应发生情况。结果:与对照组比较,治疗组SCCAg、CYFRA21-1下降较显著,差异有统计学意义(P<0.05)。治疗组患者生存质量优于对照组,差异有统计学意义(P<0.05)。观察组患者中医证候的改善情况及不良反应的程度比较,治疗组优于对照组,差异有统计学意义(P<0.05)。结论:紫龙金片与PC化疗方案联用治疗原发性非小细胞肺癌,可显著降低SCCAg、CYFRA21-1水平,缓解临床症状,提高生存质量,具有减毒增效的作用。

Objective ：To observe the clinical efficacy of Zilongjin tablets combined with PC chemotherapy in treatment of primary Non-small Cell Lung Cancer. Methods：Fifty-three patients were randomly divided into control group and treatment group （4 cases falls off during the treatment）. The control group of 24 cases were given PC chemotherapy,while 25 cases in the treatment group were treated with Zilongjin Tablets in addition to that of the control group. The levels of SCC and CYFRA21-1 were compared be- tween the two groups, and both groups＇ quality of life was evaluated. The TCM syndrome score and the adverse reactions were ob- served. Resuhs：Compared with those of the control group,the levels of SCC and CYFRA21-1 in the treatment group were signifi- cantly lower（P 〈 0.05 ）. The quality of life of the treatment group was better than that of the control group, the difference being statistically significant（P 〈 0.05 ）. The improvement of TCM syndromes and the degree of adverse reactions in the treatment group were better than those in the control group, the difference being statistically significant （ P 〈0.05 ）. Conclusion ： Zilongjin tablets combined with PC chemotherapy in treatment of primary Non-small cell lung cancer can significantly reduce the level of SCC and CYFRA21-1 ,relieve the clinical symptoms,reduce toxicity, improve patients＇ quality of life and increase the clinical efficacy sig- nificantly.